文献速递肿瘤 PET/CT神经核医学

胰高血糖素瘤分子影像病例系列:初始治疗后镓-68-DOTATATE PET/CT随访与再评估结果与其他起源神经内分泌肿瘤相似

A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation.
PubMed 文献 · Clin Nucl Med · 2018-01-01

本文报告3例胰高血糖素瘤患者,均经组织学和/或血清胰高血糖素升高诊断,并至少接受1次镓-68-DOTATATE PET/CT扫描。病例提示,基于生长抑素受体的影像学可能可用于胰高血糖素瘤疾病状态的再评估,方式与其他起源神经内分泌肿瘤已确立的应用相似。

要点

  • 3例胰高血糖素瘤患者均经组织学和/或血清胰高血糖素升高诊断。
  • 每例患者至少接受1次镓-68-DOTATATE PET/CT扫描。
  • 病例提示生长抑素受体影像可能用于胰高血糖素瘤再评估。

核心结论

  • 所呈现的病例提示,基于生长抑素受体的影像学可能可用于胰高血糖素瘤患者的疾病状态再评估,方式与其他起源神经内分泌肿瘤已确立的应用相似。

研究设计与样本

  • 本文为病例系列,纳入3例胰高血糖素瘤患者,每例至少接受1次镓-68-DOTATATE PET/CT扫描。
  • 所有患者均经组织学和/或血清胰高血糖素升高诊断。

主要发现

  • 原文未报告具体影像学表现、病灶数量、摄取程度或随访结果数值。

关键数值与推荐

  • 原文未报告诊断阈值、定量标准或推荐条款。

临床怎么用

  • 原文未据此给出推荐;作者在结论中提出,基于生长抑素受体的影像学可能可用于胰高血糖素瘤的疾病状态再评估。

局限性

  • 原文指出胰高血糖素瘤是极罕见的胰腺神经内分泌肿瘤,关于其生长抑素受体影像特征的数据稀少,且仅涉及初始诊断情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagonoma is an extremely rare, glucagon-secreting neuroendocrine tumor of the pancreas. Only sparse data are available about the characteristics of this tumor in somatostatin receptor imaging and only for the situation of initial diagnosis. We present a series of 3 glucagonoma patients who underwent at least 1 Ga-DOTATATE PET/CT scan. All patients were diagnosed by either histology and/or elevated serum levels of glucagon. The presented cases suggest that somatostatin receptor-based imaging can probably be used for re-evaluation of disease status in patients with glucagonoma in a similar way as it is already established for neuroendocrine tumors of other origin.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rottenburger C, Papantoniou D, Mandair D, et al. A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation. Clin Nucl Med. 2018. PMID: 29432346. doi:10.1097/RLU.0000000000002005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。